Jinghua Pharmaceutical Group Co., Ltd.

Shenzhen Stock Exchange 002349.SZ

Jinghua Pharmaceutical Group Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2023: 0.01

Jinghua Pharmaceutical Group Co., Ltd. Debt to Equity Ratio is 0.01 for the year ending December 31, 2023, a -7.25% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Jinghua Pharmaceutical Group Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2022 was 0.01, a -89.18% change year over year.
Jinghua Pharmaceutical Group Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2021 was 0.09, a -38.22% change year over year.
Jinghua Pharmaceutical Group Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2020 was 0.14, a -48.95% change year over year.
Jinghua Pharmaceutical Group Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2019 was 0.28, a 52.11% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

Shenzhen Stock Exchange: 002349.SZ

Jinghua Pharmaceutical Group Co., Ltd.

CEO	Mr. Yunzhong Zhou
IPO Date	Feb. 3, 2010
Location	China
Headquarters	No 2-02#, Xrd Between 3 Haibin Rd & 2 To
Employees	1,493
Sector	Health Care
Industries Pharmaceuticals Petrochemicals

Description

Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenylbutazone, Primidone, Phenobarbital, Fluorouracil, Propylthiouracil, Piroxicam, and Flucytosine APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. Jinghua Pharmaceutical Group Co., Ltd. was founded in 1957 and is based in Nantong, China.

Key trends

Past 5 years